ClinicalTrials.gg
CompletedNCT00136981RADIANCE 1Updated Apr 22, 2015

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Hypercholesterolemia, Familial and Hyperlipidemia, sponsored by Pfizer. Completed at 35 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-04-22.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.

Enrollment
2nd of 33
800 · median 153
Started
2003
with 3 others
Phase 3
14 of 35
3 open now
Registered
4th of 35
by date
Lead sponsor
3 of 35
Pfizer

Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2003, is one of 14 in phase 3, and was the 4th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, or all of them as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with heterozygous familial hypercholesterolemia

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Hypercholesterolemia, Familial
  • Hyperlipidemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Heterozygous Familial Hypercholesterolemia
  • At least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
800 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in intima media thickness as measures by carotid ultrasound

Secondary outcomes

  1. Changes in levels of lipids and other biomarkers.

07

Study locations

35 sites
  • Pfizer Investigational Site
    Hartford, Connecticut, United States
  • Pfizer Investigational Site
    Boston, Massachusetts, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota, United States
  • Pfizer Investigational Site
    New York, New York, United States
  • Pfizer Investigational Site
    Houston, Texas, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah, United States
  • Pfizer Investigational Site
    Seattle, Washington, United States
  • Pfizer Investigational Site
    Vancouver, British Columbia, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec, Canada
  • Pfizer Investigational Site
    Montreal, Quebec, Canada
  • Pfizer Investigational Site
    Quebec, Canada
  • Pfizer Investigational Site
    Prague 4, Czech Republic
  • Pfizer Investigational Site
    Prague, Czech Republic
  • Pfizer Investigational Site
    Kuopio, Finland
  • Pfizer Investigational Site
    OYS, Finland
  • Pfizer Investigational Site
    PARIS Cedex, France
  • Pfizer Investigational Site
    Toul Cedex, France
  • Pfizer Investigational Site
    Brescia, Italy
  • Pfizer Investigational Site
    Pavia, Italy
  • Pfizer Investigational Site
    Alkmaar, Netherlands
  • Pfizer Investigational Site
    Amsterdam, Netherlands
  • Pfizer Investigational Site
    Delft, Netherlands
  • Pfizer Investigational Site
    Goes, Netherlands
  • Pfizer Investigational Site
    Groningen, Netherlands
  • Pfizer Investigational Site
    Hoorn, Netherlands
  • Pfizer Investigational Site
    Leiden, Netherlands
  • Pfizer Investigational Site
    Nijmegen, Netherlands
  • Pfizer Investigational Site
    Rotterdam, Netherlands
  • Pfizer Investigational Site
    Sliedrecht, Netherlands
  • Pfizer Investigational Site
    Utrecht, Netherlands
  • Pfizer Investigational Site
    Waalwijk, Netherlands
  • Pfizer Investigational Site
    Parow, Cape Town, South Africa
  • Pfizer Investigational Site
    Parktown, Johannesburg, South Africa
  • Pfizer Investigational Site
    Cape Town, South Africa
08

References and documents

Publications

  • Tajik P, Meijer R, Duivenvoorden R, Peters SA, Kastelein JJ, Visseren FJ, Crouse JR 3rd, Palmer MK, Raichlen JS, Grobbee DE, Bots ML. Asymmetrical distribution of atherosclerosis in the carotid artery: identical patterns across age, race, and gender. Eur J Prev Cardiol. 2012 Aug;19(4):687-97. doi: 10.1177/1741826711410821. Epub 2011 May 25. PubMed 21613319 ↗
  • Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and Radiance 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med. 2010 Sep;42(6):447-64. doi: 10.3109/07853890.2010.499132. PubMed 20645885 ↗
  • Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and 2 Study Groups. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. J Atheroscler Thromb. 2010 May;17(5):526-35. doi: 10.5551/jat.3269. Epub 2010 Mar 13. PubMed 20228610 ↗
  • Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum In: Circulation. 2009 Feb 10;119(5):e197. PubMed 19029469 ↗
  • Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML; RADIANCE 1 and 2 Study Investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin. 2007 Apr;23(4):885-94. doi: 10.1185/030079907x182121. PubMed 17407645 ↗
  • Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007 Apr 19;356(16):1620-30. doi: 10.1056/NEJMoa071359. Epub 2007 Mar 26. PubMed 17387131 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2005
First posted
Aug 29, 2005
Start
Dec 2003
CompletionActual
Nov 2006
Last update
Apr 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00136981
Lead sponsor
Pfizer
First posted
Aug 29, 2005
Start date
Dec 2003
Completion
Nov 2006
Last update
Apr 22, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin

Start the discussion